Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00034593
NCT00034593
Completed
Phase 2

A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Eli Lilly and Company2 sites in 2 countriesStarted: May 1, 2002Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsUrologic Neoplasms
DrugsALIMTAgemcitabine

Overview

Phase
Phase 2
Status
Completed
Locations
2
OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.

Study Design

Study Type
Interventional
Primary Purpose
Treatment

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body.
  • •You must have at least one tumor that can be physically measured or scanned by x-ray.
  • •You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago.

Exclusion Criteria

  • •You may not have used an experimental medicine or device within the past month.
  • •Cancer that has spread to your brain.
  • •If you are unwilling or unable to take folic acid or vitamin B12 supplements.

Investigators

Sponsor Class
Industry

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 2
A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the UrotheliumUrologic NeoplasmsMetastases, Neoplasm
NCT00035061Eli Lilly and Company
Terminated
Phase 2
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder CancerUrinary Bladder Neoplasms
NCT02560038The University of Texas Health Science Center, Houston3
Completed
Phase 2
A Trial for Patients With Advanced/Recurrent Cervical CancerCervical Intraepithelial NeoplasiaUterine NeoplasmsGenital Neoplasms, Female
NCT00190983Eli Lilly and Company29
Completed
Phase 2
Pemetrexed as the First Treatment in Advanced or Metastatic Breast CancerBreast CancerBreast Neoplasms, MaleCarcinoma, Ductal
NCT00106002Eli Lilly and Company37
Completed
Phase 2
Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is MetastaticPancreatic Cancer
NCT00490373Eli Lilly and Company52